Global Fusion Biopsy Market to Register Sustainable Growth at a CAGR of ~6% by 2034 | DelveInsight

The fusion biopsy market is witnessing strong growth due to the rising prevalence of prostate cancer and increasing adoption of MRI-ultrasound fusion technology for accurate diagnosis. Growing awareness of early cancer detection, coupled with advancements in imaging systems and biopsy guidance platforms, is driving demand for fusion biopsy procedures. Favorable reimbursement policies and expanding healthcare infrastructure are further supporting market expansion, particularly in North America and Europe. Additionally, the increasing shift toward minimally invasive, precision-guided diagnostic techniques is expected to sustain the market's growth over the coming years.

New York, USA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Global Fusion Biopsy Market to Register Sustainable Growth at a CAGR of ~6% by 2034 | DelveInsight

The fusion biopsy market is witnessing strong growth due to the rising prevalence of prostate cancer and increasing adoption of MRI-ultrasound fusion technology for accurate diagnosis. Growing awareness of early cancer detection, coupled with advancements in imaging systems and biopsy guidance platforms, is driving demand for fusion biopsy procedures. Favorable reimbursement policies and expanding healthcare infrastructure are further supporting market expansion, particularly in North America and Europe. Additionally, the increasing shift toward minimally invasive, precision-guided diagnostic techniques is expected to sustain the market's growth over the coming years.

DelveInsight’s Fusion Biopsy Market Insights report provides the current and forecast market analysis, individual leading fusion biopsy companies’ market shares, challenges, fusion biopsy market drivers, barriers, trends, and key fusion biopsy companies in the market.

Fusion Biopsy Market Summary

• 2025 Fusion Biopsy Market Size: ~USD 798 Million
• 2034 Projected Fusion Biopsy Market Size: ~USD 1.5 Billion
• Fusion Biopsy Market Growth Rate (2026-2034): ~7% 
• Largest Fusion Biopsy Market: North America
• Largest Product Segment: Accessories Category
• Key Companies in the Fusion Biopsy Market: Koninklijke Philips N.V., KOELIS S.A., innoMedicus Ltd., Siemens Healthineers AG, MedCom GmbH, Exact Imaging Inc., Focal Healthcare Inc., Biobot Surgical Pte. Ltd., Esaote S.p.A., GE HealthCare Technologies Inc., Hitachi Medical Systems (Hitachi, Ltd.), Canon Medical Systems Corporation, BK Medical Holding Company, Inc., Eigen, Inc., UroMedTech GmbH, D&K Technologies Pvt. Ltd., and others

To read more about the latest highlights related to the fusion biopsy market, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/fusion-biopsy-market

Key Factors Contributing to the Rise in Growth of the Fusion Biopsy Market

• Increasing Prevalence of Prostate Cancer: The rising global incidence of prostate cancer is significantly driving demand for advanced diagnostic technologies. Fusion biopsy enables more accurate detection of clinically significant tumors, supporting earlier diagnosis and improved treatment outcomes.
• Growing Adoption of MRI-Targeted Biopsy Techniques: The widespread use of multiparametric MRI (mpMRI) before biopsy has increased the adoption of MRI-ultrasound fusion biopsy systems. These techniques improve lesion localization while reducing unnecessary biopsies and overdiagnosis.
• Higher Diagnostic Accuracy Compared to Conventional Biopsy: Fusion biopsy offers superior sensitivity and precision by combining real-time ultrasound with pre-acquired MRI images. This approach enhances the detection of aggressive cancers while minimizing the likelihood of missing clinically significant lesions.
• Technological Advancements in Imaging and Navigation Systems: Continuous innovations in imaging software, artificial intelligence, robotic assistance, and real-time tracking technologies have improved the efficiency, reproducibility, and accuracy of fusion biopsy procedures, encouraging broader clinical adoption.
• Rising Preference for Minimally Invasive Diagnostic Procedures: Patients and healthcare providers increasingly favor minimally invasive procedures that reduce complications and recovery time. Fusion biopsy offers a safer and more targeted alternative to systematic biopsy, improving patient experience.
• Growing Awareness of Early Cancer Detection: Increased public awareness, screening initiatives, and physician education regarding prostate cancer have led to higher diagnostic rates. Early detection programs are creating sustained demand for advanced biopsy technologies.
• Supportive Clinical Guidelines and Evidence-Based Recommendations: International clinical guidelines increasingly recommend mpMRI-guided targeted biopsy for patients with suspected prostate cancer. Strong clinical evidence demonstrating improved diagnostic performance is accelerating market acceptance.
• Increasing Investments in Research and Product Innovation: Medical device manufacturers are investing heavily in research and development to introduce more compact, user-friendly, and AI-enabled fusion biopsy platforms. These innovations enhance workflow efficiency and broaden the technology's clinical applications.
• Growing Geriatric Population: As prostate cancer predominantly affects older men, the expanding aging population worldwide is contributing to a larger patient pool. This demographic trend is expected to sustain long-term demand for fusion biopsy procedures and related technologies.

Get a sneak peek at the fusion biopsy market dynamics @ Fusion Biopsy Market Trends

Regional Fusion Biopsy Market Insights

North America

• North America held the largest share of the fusion biopsy market, accounting for 42.67% in 2025. 
• The region's leadership is supported by its well-established healthcare infrastructure, widespread adoption of advanced imaging technologies such as magnetic resonance imaging (MRI) and Ultrasound Imaging, and the increasing incidence of prostate cancer. 
• Furthermore, the strong presence of major industry participants, favorable reimbursement policies, and growing emphasis on early and precise cancer detection are expected to accelerate the adoption of fusion biopsy systems throughout North America.

Europe

• The European fusion biopsy market is experiencing robust growth, driven by the increasing incidence of prostate cancer, wider adoption of advanced diagnostic technologies, and the strong presence of prominent medical device manufacturers. 
• Major markets including Germany, the U.K., and France are making significant investments in precision diagnostics and imaging infrastructure, accelerating the uptake of fusion biopsy systems that combine magnetic resonance imaging (MRI) and Ultrasound Imaging for more accurate, targeted cancer detection. 
• Furthermore, favorable clinical guidelines from European urology organizations, along with rising awareness of the importance of early diagnosis, are supporting market expansion. 
• Ongoing product innovations and recent launches across the region are also contributing to the market's positive growth trajectory.

Asia-Pacific

• The Asia Pacific region is becoming a key growth hub for the fusion biopsy market, supported by expanding healthcare infrastructure, increasing awareness of early cancer diagnosis, and the growing incidence of prostate cancer in countries including China, India, and Japan. 
• Healthcare providers across the region are investing heavily in advanced diagnostic technologies, particularly magnetic resonance imaging (MRI) and Ultrasound Imaging-based systems that enable accurate fusion biopsy procedures. 
• Government-led healthcare initiatives, improved access to medical services, and the increasing preference for minimally invasive diagnostic techniques are further driving demand for precision diagnostic solutions. 
• Moreover, the rapidly aging population, especially in Japan and South Korea, is contributing to market expansion, as advancing age is a major risk factor for prostate cancer.
• Overall, advancements in healthcare infrastructure, continued technological progress, the rising burden of prostate cancer, and ongoing product innovation are fueling the adoption of fusion biopsy systems across the Asia Pacific region, positioning it as one of the fastest-growing markets worldwide.

To know more about why North America is leading the market growth in the fusion biopsy market, get a snapshot of the Fusion Biopsy Market Share

Recent Developmental Activities in the Fusion Biopsy Market

• In April 2026, KOELIS introduced AI-powered ProMap® Smart software to streamline MRI-ultrasound fusion workflows and improve clinical efficiency.
• In July, 2025, Koninklijke Philips N.V. received FDA 510(k) clearance for the latest version of its UroNav fusion biopsy/navigation system, enhancing image-guided prostate cancer diagnosis with improved annotation workflows and precision targeting.
• In March 2025, the University of Oxford introduced a novel MRI-ultrasound fusion biopsy technique, aimed at reducing unnecessary biopsies and improving the detection of clinically significant prostate cancers.
• In March, 2025, KOELIS showcased advanced enhancements to its Trinity® fusion biopsy platform at the European Association of Urology (EAU) Congress, focusing on improved workflow and targeted biopsy precision.

What is Fusion Biopsy?

Fusion biopsy is an advanced diagnostic procedure that combines real-time ultrasound imaging with previously acquired magnetic resonance imaging (MRI) scans to improve the accuracy of tissue sampling, particularly for prostate cancer detection. During the procedure, specialized software fuses detailed MRI images, which identify suspicious lesions, with live ultrasound guidance, enabling clinicians to precisely target areas that may harbor clinically significant cancer. Compared with conventional systematic biopsy, fusion biopsy increases the detection of aggressive tumors while reducing the likelihood of identifying low-risk cancers that may not require immediate treatment. This minimally invasive technique enhances diagnostic confidence, supports more personalized treatment decisions, and has become an increasingly preferred approach for patients with elevated prostate-specific antigen (PSA) levels, abnormal digital rectal examination findings, or suspicious lesions detected on multiparametric MRI.

Fusion Biopsy Market Report Metrics	Details
Coverage	Global
Study Period	2023–2034
Fusion Biopsy Market CAGR	~7%
Fusion Biopsy Market Size by 2034	~USD 1.5 Billion
Key Fusion Biopsy Companies	Koninklijke Philips N.V., KOELIS S.A., innoMedicus Ltd., Siemens Healthineers AG, MedCom GmbH, Exact Imaging Inc., Focal Healthcare Inc., Biobot Surgical Pte. Ltd., Esaote S.p.A., GE HealthCare Technologies Inc., Hitachi Medical Systems (Hitachi, Ltd.), Canon Medical Systems Corporation, BK Medical Holding Company, Inc., Eigen, Inc., UroMedTech GmbH, D&K Technologies Pvt. Ltd., and others

Fusion Biopsy Market Assessment

• Fusion Biopsy Market Segmentation
  • Fusion Biopsy Market Segmentation By Products: Equipment and Consumables & Accessories
  • Fusion Biopsy Market Segmentation By Route of Biopsy: Transrectal and Transperineal
  • Fusion Biopsy Market Segmentation By End Users: Hospitals, Diagnostic Imaging Centers, and Others
  • Fusion Biopsy Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the fusion biopsy market are set to emerge as the trendsetter explore @ Fusion Biopsy Market Analysis

Table of Contents 

1	Fusion Biopsy Market Report Introduction
2	Fusion Biopsy Market Executive Summary
3	Fusion Biopsy Market Key Factors Analysis
4	Impact Analysis
5	Regulatory Analysis
6	Fusion Biopsy Market Porter’s Five Forces Analysis
7	Fusion Biopsy Market Assessment
8	Competitive Landscape
9	Startup Funding & Investment Trends
10	Fusion Biopsy Market Company and Product Profiles
11	KOL Views
12	Project Approach
13	About DelveInsight
14	Disclaimer & Contact Us

Interested in knowing the fusion biopsy market share by 2034? Click to get a snapshot of the Fusion Biopsy Market Size 

Related Reports

Biopsy Devices Market

Biopsy Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key biopsy devices companies, including Boston Scientific Corporation, Cardinal Health, Medtronic, BD, Cook, Devicor Medical Products Inc., B. Braun Melsungen AG, ARGON MEDICAL, OLYMPUS CORPORATION, FUJIFILM, INRAD Inc., Hologic Inc., C. R. Bard, Dr. Japan Co Ltd., Limaca-medical, Owlstone Medical Ltd., Zamar Care, KOELIS, ST. STONE MEDICAL DEVICES PVT LTD, Iscon Surgicals Ltd., and others.

Digital Biopsy Market

Digital Biopsy Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key digital biopsy companies, including DermaSensor, Inc., SciBase, VITA IMAGING, Inc., MetaOptima Technology Inc., VPIX Medical Inc., Mauna Kea Technologies, Skin Analytics, Trafita Medical System, BRAINSPEC, Imaging Biometrics, LLC, Optovibronex, LLC, FUJIFILM Holdings Corporation, Canon Inc., VivaScope GmbH, and others.

Magnetic Resonance Imaging Devices Market

Magnetic Resonance Imaging Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MRI devices companies, including General Electric Company, FUJIFILM Holdings Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, ESAOTE SPA, Aspect Imaging Ltd., Bruker Corporation, Aurora Healthcare US Corp., FONAR Corp., Neusoft Medical Systems Co., Ltd., Shenzhen Anke High-Tech Co. Ltd., Shenzhen Basda Medical Apparatus Co. Ltd., Time Medical Holding, Hyperfine, Alltech Medical Systems, InnerVision MRI Ltd., Magnetica Limited, IMRIS, Deerfield Imaging, Inc., and others.

AI in Ultrasound Imaging Market

AI in Ultrasound Imaging Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in ultrasound imaging companies, including GE HealthCare Technologies Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Canon Medical Systems Corporation, Samsung Medison Co., Ltd., FUJIFILM Holdings Corporation, Butterfly Network, Inc., Mindray Medical International Limited, Exo Imaging, Inc., Clarius Mobile Health Corp., and others.

Prostate Cancer Market

Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679